SCHEMBL22498299

SCHEMBL22498299

CC(c1oc(=O)c2ccccc2c1-c1cccc(C2CCCN2C)c1)n1nc(-c2cncc(O)c2)c2c(N)ncnc21

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 17/20 0.48
▸ PIK3CG P48736 11/20 0.48
▸ PIK3CB P42338 10/20 0.48
▸ PIK3CA P42336 7/20 0.48
▸ ABL1 P00519 3/20 0.42
▸ EGFR P00533 3/20 0.42
▸ HCK P08631 3/20 0.42
▸ SRC P12931 3/20 0.42
▸ KDR P35968 3/20 0.42
▸ MTOR P42345 3/20 0.42
▸ EPHB4 P54760 3/20 0.42
▸ PRKDC P78527 3/20 0.42
▸ PI4KB Q9UBF8 3/20 0.42
▸ PIK3C2B O00750 1/20 0.41
▸ PIK3R1 P27986 1/20 0.41
▸ CSNK1E P49674 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22498269 1.00 PIK3CD (0.48) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL22504973 1.00 PIK3CD (0.48) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL29641627 1.00 PIK3CD (0.48) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL24494689 0.92 PIK3CD (0.47) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL22504993 0.87 PIK3CD (0.41) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL30679714 0.87 PIK3CD (0.41) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL24494704 0.87 PIK3CD (0.41) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL16783537 0.85 PIK3CD (0.53) PIK3CDPIK3CGPIK3CBPIK3CAABL1
SCHEMBL16806468 0.85 PIK3CD (0.53) PIK3CDPIK3CGPIK3CBPIK3CAABL1
Hydrochloric Acid SCHEMBL16783551 0.85 PIK3CD (0.52) PIK3CDPIK3CGPIK3CBPIK3CAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527797-B2 Isochromene derivatives as phosphoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-20 — — US disclosed
EP-3947384-B1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2023-11-01 — — EP disclosed
EP-3947384-B1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2023-11-01 — — EP disclosed
US-20220175784-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-09 — — US disclosed
US-20220175784-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-09 — — US disclosed
EP-3947384-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-02-09 — — EP disclosed
WO-2020200918-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-10-08 — — WO disclosed
WO-2020200918-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175784-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS PIKFYVE, PDPK1, PIK3R5 PIK3CD 5/4885PIK3CG 13/4885PIK3CB 4/4885
US-12527797-B2 Isochromene derivatives as phosphoinositide 3-kinases inhibitors PIK3R5, PIK3CD, PIK3R4 PIK3CD 2/4885PIK3CG 7/4885PIK3CB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback